Pre-HSCT treatment guidelines for JMML
| Asymptomatic . | High white blood cell count, pulmonary problems, and/or prominent organomegaly . | Moderately/Severely Ill . |
|---|---|---|
| No pre-HSCTtherapy | Oral 6-mercaptopurine (50 mg/m2 per day) | Low-dose intravenous cytarabine (40 mg/m2 per day × 5 days); if no improvement of symptoms: high-dose intravenous cytarabine (2 g/m2 per day × 5 days) + fludarabine (30 mg/m2 per day × 5 days) |
| Asymptomatic . | High white blood cell count, pulmonary problems, and/or prominent organomegaly . | Moderately/Severely Ill . |
|---|---|---|
| No pre-HSCTtherapy | Oral 6-mercaptopurine (50 mg/m2 per day) | Low-dose intravenous cytarabine (40 mg/m2 per day × 5 days); if no improvement of symptoms: high-dose intravenous cytarabine (2 g/m2 per day × 5 days) + fludarabine (30 mg/m2 per day × 5 days) |
These pre-HSCT guidelines are provided for physician consideration.